New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
08:07 EDTABT, FII, NCIT, DELL, ESI, ABBVAbbVie to join S&P 100, 500 in place of Dell, Federated Investors
S&P Dow Jones Indices announced last night that it will make the following changes to the S&P 100, 500, MidCap 400 and SmallCap 600 indices after the close of trading on Monday, December 31: AbbVie (ABBV) will replace Dell (DELL) in the S&P 100, and Federated Investors (FII) in the S&P 500. Federated will replace ITT Educational Services (ESI) in the S&P MidCap 400, and ITT Educational Services will replace NCI Inc. (NCIT) in the S&P SmallCap 600. S&P 100 and 500 constituent Abbott (ABT) is spinning off AbbVie in a transaction expected to be completed after the close of trading on December 31. Abbott will remain in the S&P 100 and 500.
News For ABBV;DELL;FII;ESI;NCIT;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
April 24, 2015
07:23 EDTABBVAbbVie price target raised to $81 from $76 at UBS
Subscribe for More Information
05:32 EDTABBVAbbVie announces priority review from FDA for OBV/PTV/r
AbbVie has announced that the FDA has accepted its New Drug Application, or NDA, and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir, or OBV/PTV/r, with ribavirin, or RBV. The NDA is for the treatment of adults with chronic genotype 4, or GT4, hepatitis C virus, or HCV, infection. AbbVie's regimen is the first all-oral, interferon-free therapy being evaluated by the FDA for patients in the United States with chronic GT4 HCV infection. This submission affirms the company's commitment to seeking access to curative therapy for patients living with chronic HCV infection. The FDA granted priority review to AbbVie for the regimen based in part on data from the PEARL-I study, which was recently published online in The Lancet. The FDA grants priority review designation to investigational therapies that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. This designation shortens the regulatory review period for non-new chemical entity NDAs from the normal 10 months to six months. AbbVie's regimen was also granted a Breakthrough Therapy designation by the FDA on June 30, 2014, a status given to investigational treatments for serious or life-threatening conditions with preliminary clinical evidence that may demonstrate substantial improvement on at least one clinically significant endpoint compared to available therapy.
April 23, 2015
16:20 EDTFIIFederated Investors reports Q1 EPS 35c, consensus 37c
Reports Q1 revenue $220.5M, consensus $222.09M.
10:02 EDTABBVAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:38 EDTABBVAbbVie says cutting Humira spending 'not a prudent strategy'
Subscribe for More Information
09:29 EDTABBVAbbVie sees Q2 EPS $1.04-$1.06, consensus $1.05
Subscribe for More Information
09:26 EDTABBVAbbVie says not completly immune to forex, but hedges protect bottom line impact
Subscribe for More Information
09:16 EDTABBVAbbVie says intends to enforce IP if Humira challenged by biosimilar applicant
Subscribe for More Information
09:07 EDTABBVAbbVie says remains on track to complete Pharmacyclics acquisition in Q2
09:04 EDTABBVAbbVie says continues to see strong underlying demand for Humira
Comment from earnings conference call.
08:19 EDTABBVEnanta announces FDA grants priority review for AbbVie treatment regimen
Subscribe for More Information
07:52 EDTABBVAbbVie expects Pharmacyclics transaction to close in Q2
Subscribe for More Information
07:51 EDTABBVAbbVie raises FY15 adjusted EPS to $4.10-$4.30 from $4.05-$4.25, consensus $4.19
Subscribe for More Information
07:51 EDTABBVAbbVie reports Q1 HUMIRA sales up 26% to $3.11B
Subscribe for More Information
07:49 EDTABBVAbbVie reports Q1 adjusted EPS 94c, consensus 85c
Reports Q1 revenue $5.04B, consensus $4.98B
April 22, 2015
15:50 EDTABBVNotable companies reporting before tomorrow's open
Subscribe for More Information
14:08 EDTABBVEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information
09:26 EDTABTAbbott sees flat growth in Molecular Diagnostics business in Q2
Sees mid-single digit growth for Global Diagnostics growth in Q2. Sees low single digit growth for Global Vascular in Q2. Expects similar double digit growth in EPD in Q2.
09:21 EDTABTAbbott sees FY15 revenue growth to be in low single digits, consensus $20.71B
Subscribe for More Information
09:20 EDTABTAbbott sees Q2 EPS 49c-51c, consensus 52c
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use